The primary endpoint of this study was OS, which was measured from the date of initiation of first-line chemotherapy to the date of death as a result of any cause or last date of follow-up. The objective of this study was to develop and validate a prognostic model allowing patients with de novo mNPC to be stratified based on their survival expectations. In the current study, variables of interest were selected based on a review of the literature. All variables included in this study were supposed to be underlying prognostic factors or confounding factors involving demographic information, clinical characteristics, tumor features, and treatment-related factors.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.